QuidelOrtho - QDEL Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $99.75
  • Forecasted Upside: 17.56 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 0 Buy Ratings
  • 1 Strong Buy Ratings
$84.85
▼ -3.35 (-3.80%)

This chart shows the closing price for QDEL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New QuidelOrtho Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for QDEL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for QDEL

Analyst Price Target is $99.75
▲ +17.56% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for QuidelOrtho in the last 3 months. The average price target is $99.75, with a high forecast of $130.00 and a low forecast of $86.00. The average price target represents a 17.56% upside from the last price of $84.85.

This chart shows the closing price for QDEL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 polled investment analysts is to buy stock in QuidelOrtho. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/6/2021
  • 1 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/4/2021
  • 1 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/3/2021
  • 1 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/3/2022
  • 1 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/1/2022
  • 1 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/30/2022
  • 1 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
10/29/2022
  • 1 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
11/28/2022

Latest Recommendations

  • 1 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/3/2022JPMorgan Chase & Co.Lower TargetNeutral$100.00 ➝ $93.00Low
10/14/2022UBS GroupUpgradeSell ➝ Neutral$86.00Low
9/19/2022CitigroupInitiated CoverageNeutral$90.00Low
7/20/2022UBS GroupInitiated CoverageSell$86.00Low
6/17/2022JPMorgan Chase & Co.Initiated CoverageUnderweight ➝ NeutralHigh
2/22/2022Raymond JamesUpgradeOutperform ➝ Strong-Buy$155.00 ➝ $130.00High
10/8/2021JPMorgan Chase & Co.Boost TargetOverweight$70.00 ➝ $80.00Medium
8/6/2021Raymond JamesBoost TargetOutperform$141.00 ➝ $155.00Low
6/28/2021Raymond JamesLower TargetOutperform$160.00 ➝ $141.00High
6/17/2021Craig HallumLower TargetBuy$296.00 ➝ $219.00Low
6/4/2021JPMorgan Chase & Co.Lower TargetUnderweight$90.00 ➝ $80.00High
5/7/2021Raymond JamesLower TargetOutperform$180.00 ➝ $160.00High
5/7/2021JPMorgan Chase & Co.Lower TargetUnderweight$95.00 ➝ $90.00High
4/23/2021JPMorgan Chase & Co.Lower Target$120.00 ➝ $95.00High
4/23/2021Piper SandlerLower Target$265.00 ➝ $140.00High
3/17/2021Raymond JamesLower TargetOutperform$245.00 ➝ $180.00N/A
3/11/2021Craig HallumLower TargetBuy$371.00 ➝ $341.00Low
3/11/2021Raymond JamesLower TargetOutperform$245.00 ➝ $180.00Low
2/25/2021Raymond JamesLower TargetOutperform$250.00 ➝ $245.00Medium
2/19/2021JPMorgan Chase & Co.Lower TargetUnderweight$175.00 ➝ $170.00High
1/22/2021Raymond JamesUpgradeMarket Perform ➝ Outperform$250.00High
10/30/2020JPMorgan Chase & Co.Boost TargetUnderweight$185.00 ➝ $190.00Medium
7/31/2020Craig HallumBoost TargetPositive ➝ Buy$306.00 ➝ $363.00Medium
7/31/2020Piper SandlerBoost TargetOverweight$250.00 ➝ $360.00High
7/8/2020Piper SandlerBoost TargetOverweight$168.00 ➝ $250.00Medium
7/7/2020Craig HallumBoost TargetBuy$170.00 ➝ $306.00Medium
5/12/2020JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$120.00 ➝ $158.00High
5/7/2020Craig HallumBoost TargetMarket Perform ➝ Buy$125.00 ➝ $170.00Medium
3/26/2020BarclaysReiterated RatingOverweight ➝ Equal Weight$90.00High
3/19/2020Raymond JamesDowngradeStrong-Buy ➝ Market PerformHigh
2/13/2020Raymond JamesBoost TargetStrong-Buy$70.00 ➝ $92.00Medium
8/29/2019Craig HallumUpgradeHold ➝ Buy$63.00 ➝ $75.00High
4/15/2019Raymond JamesBoost TargetStrong-Buy ➝ Strong-Buy$72.00 ➝ $74.00Medium
3/18/2019BarclaysBoost TargetOverweight ➝ Overweight$74.00 ➝ $77.00High
2/15/2019BarclaysReiterated RatingBuy$74.00Low
2/14/2019Craig HallumBoost TargetHold$51.00 ➝ $63.00High
12/11/2018Raymond JamesLower TargetStrong-Buy ➝ Strong-Buy$80.00 ➝ $70.00Medium
12/10/2018Craig HallumDowngradeBuy ➝ Hold$80.00 ➝ $51.00High
12/10/2018BarclaysLower TargetOverweight ➝ Overweight$85.00 ➝ $77.00High
10/23/2018Raymond JamesReiterated RatingStrong-Buy ➝ Strong-Buy$80.00Medium
8/8/2018Craig HallumBoost TargetBuy$64.00 ➝ $80.00High
8/8/2018Piper Jaffray CompaniesReiterated RatingIn-Line ➝ Overweight$74.00High
8/6/2018BarclaysBoost TargetOverweight ➝ Overweight$65.00 ➝ $78.00Medium
5/10/2018BarclaysReiterated RatingBuy$65.00High
4/13/2018William BlairReiterated RatingBuyLow
4/4/2018Piper Jaffray CompaniesReiterated RatingBuy$63.00Low
4/2/2018BarclaysBoost TargetOverweight ➝ Overweight$60.00 ➝ $63.00Low
3/26/2018Craig HallumInitiated CoverageBuy$62.00Low
3/8/2018Raymond JamesUpgradeOutperform ➝ Strong-Buy$55.00 ➝ $47.00Medium
3/8/2018UBS GroupUpgradeOutperform ➝ Strong-BuyHigh
1/24/2018Piper Jaffray CompaniesReiterated RatingBuy$60.00Low
1/22/2018BarclaysBoost TargetOverweight ➝ Overweight$50.00 ➝ $60.00High
1/4/2018CL KingUpgradeNeutral ➝ Buy$52.00High
12/14/2017Piper Jaffray CompaniesReiterated RatingBuy$50.00Low
(Data available from 11/28/2017 forward)

News Sentiment Rating

0.78 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 14 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
5/2/2022
  • 6 very positive mentions
  • 18 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/1/2022
  • 4 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/1/2022
  • 6 very positive mentions
  • 22 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/31/2022
  • 3 very positive mentions
  • 15 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
8/30/2022
  • 3 very positive mentions
  • 16 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/29/2022
  • 2 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/29/2022
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/28/2022

Current Sentiment

  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
QuidelOrtho logo
QuidelOrtho Corporation focuses on the development and manufacture of diagnostic testing technologies across the continuum of healthcare testing needs. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; and analyzers and amplification systems. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was founded in 1979 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $84.85
Low: $84.17
High: $88.34

50 Day Range

MA: $81.37
Low: $67.49
High: $93.35

52 Week Range

Now: $84.85
Low: $66.88
High: $180.06

Volume

509,654 shs

Average Volume

674,446 shs

Market Capitalization

$5.60 billion

P/E Ratio

4.51

Dividend Yield

N/A

Beta

0.28

Frequently Asked Questions

What sell-side analysts currently cover shares of QuidelOrtho?

The following sell-side analysts have issued reports on QuidelOrtho in the last twelve months: Citigroup Inc., JPMorgan Chase & Co., Raymond James, StockNews.com, TheStreet, and UBS Group AG.
View the latest analyst ratings for QDEL.

What is the current price target for QuidelOrtho?

4 Wall Street analysts have set twelve-month price targets for QuidelOrtho in the last year. Their average twelve-month price target is $99.75, suggesting a possible upside of 16.6%. Raymond James has the highest price target set, predicting QDEL will reach $130.00 in the next twelve months. UBS Group AG has the lowest price target set, forecasting a price of $86.00 for QuidelOrtho in the next year.
View the latest price targets for QDEL.

What is the current consensus analyst rating for QuidelOrtho?

QuidelOrtho currently has 3 hold ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe QDEL will outperform the market and that investors should add to their positions of QuidelOrtho.
View the latest ratings for QDEL.

What other companies compete with QuidelOrtho?

How do I contact QuidelOrtho's investor relations team?

QuidelOrtho's physical mailing address is 9975 SUMMERS RIDGE ROAD, SAN DIEGO CA, 92121. The company's listed phone number is (858) 552-1100 and its investor relations email address is [email protected] The official website for QuidelOrtho is www.quidel.com. Learn More about contacing QuidelOrtho investor relations.